| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | 218,375 | 191,203 | 195,999 | 170,992 |
| Cost of revenue (excluding amortization and depreciation) | 13,564 | 14,725 | 12,329 | 11,912 |
| Research and development | 46,227 | 52,677 | 48,791 | 40,162 |
| Selling, general and administrative | 208,137 | 184,996 | 169,297 | 150,235 |
| Gain in fair value of contingent consideration | -1,496 | 590 | -9,068 | 13,185 |
| Intangible asset amortization | 1,589 | 1,572 | 1,607 | 1,607 |
| Total operating expenses | 268,021 | 254,560 | 222,956 | 217,101 |
| Loss from operations | -49,646 | -63,357 | -26,957 | -46,109 |
| Interest expense, net | -1,540 | -1,185 | -1,172 | -1,120 |
| Gain on debt extinguishment | 0 | - | 0 | - |
| Loss before income taxes | -51,186 | -64,542 | -28,129 | -47,229 |
| Income tax benefit (expense) | 128 | 0 | 430 | - |
| Net loss | -51,314 | -64,542 | -28,559 | -47,229 |
| Basic EPS | -0.99 | -1.26 | -0.564 | -0.94 |
| Diluted EPS | -0.99 | -1.26 | -0.564 | -0.94 |
| Basic Average Shares | 51,799,708 | 51,198,349 | 50,653,697 | 50,021,851 |
| Diluted Average Shares | 51,799,708 | 51,198,349 | 50,653,697 | 50,021,851 |
Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM)